Digitisation | September 11, 2025
Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The facility has been designed with a dual focus on efficiency and sustainability
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Subscribe To Our Newsletter & Stay Updated
